Vanguard Portfolio Management’s Protalix BioTherapeutics PLX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.54M Buy
557,199
+46,560
+9% +$116K ﹤0.01% 2798
2026
Q2
$1.19M Buy
510,639
+78,154
+18% +$166K ﹤0.01% 2908
2026
Q1
$938K Buy
+432,485
New +$1.07M ﹤0.01% 2813

Other funds holding PLX

Vanguard Portfolio Management's PLX Position: Q3 2026 in Review

Vanguard Portfolio Management increased its Protalix BioTherapeutics (PLX) stake by 9.1% in Q3 2026, buying an estimated $116K and bringing the position to 557,199 shares worth $1.54M. The position accounts for ﹤0.01% of the portfolio, ranked #2798.

Vanguard Portfolio Management first reported a position in PLX in Q1 2026 and has held it in 3 quarters since. 107 funds tracked by Wall St. Rank hold PLX as of Q3 2026.

  • Vanguard Portfolio Management held 557,199 shares of Protalix BioTherapeutics worth $1.54M as of Q3 2026.
  • Vanguard Portfolio Management bought 46,560 Protalix BioTherapeutics shares in Q3 2026, an estimated $116K.
  • Protalix BioTherapeutics made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q3 2026, its #2798 holding.
  • Vanguard Portfolio Management first reported a position in Protalix BioTherapeutics in Q1 2026 and has held it in 3 quarters since.
  • 107 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q3 2026.

Based on Vanguard Portfolio Management's 13F filing for Q3 2026, filed 13 Nov 2026.